Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release

Minerva Anestesiologica

Volumn 81, Issue 2, 2015, Pages 157-165

  Vaschetto, R ^a   Navalesi, P ^a,b,c   Clemente, N ^a   Boggio, E ^a   Vvalsecchi, S ^a   Olivieri, C ^a   Soluri, M F ^a   Kroumova, V ^d   Foniao, P ^d   Dinatale, C ^d   Borre S ^c   Fortina, G ^d   Umberto, D ^a   Della Corte, F ^a   Chiocchetti, A ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b CRRF Mons Luigi Novarese   (Italy)

^c SANT'ANDREA HOSPITAL   (Italy)

^d ALS Center   (Italy)

Author keywords

Intensive care unit; Sepsis; Septic; Shock

Indexed keywords

BIOLOGICAL MARKER; OSTEOPONTIN; RECOMBINANT PROTEIN; SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; CALCITONIN;

ADULT; AGED; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INTENSIVE CARE UNIT; MALE; MONOCYTE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; GENETICS; KINETICS; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOMARKERS; CALCITONIN; FEMALE; GENE EXPRESSION; HUMANS; KINETICS; MALE; MIDDLE AGED; MONOCYTES; OSTEOPONTIN; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; SHOCK, SEPTIC;

EID: 84924237409     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
2. Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R et al. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003;168:77-84.
3. Levy MM. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. 2003.
4. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR et al. Procalcitonin and C reactive protein in hospitalised adult patients with community acquired pneumonia, exacerbation of asthma and chronic obstructive pulmonary disease. Chest 2011;139;1410.
5. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010;38:2229-41.
6. De WH, Sweep F, Brunner N, Heuvel J, Beex L, Grebenschikov N et al. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. Int J Cancer 1998;77:236-42.
7. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006;311:656-9.
8. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999;79:717-22.
9. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1868-76.
10. Ostrowski SR, Ullum H, Goka BQ, Hoyer-Hansen G, Obeng-Adjei G, Pedersen BK et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005;191:1331-41.
11. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004;10:409-15.
12. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004;36:14-9.
13. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002;6:686-92.
14. Pappot H, Hoyer-Hansen G, Ronne E, Hansen HH, Brunner N, Dano K et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997;33:867-72.
15. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999;91:869-74.
16. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011;15:R63.
17. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008;27:375-83.
18. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997;18:415-7.
19. van der Windt GJ, Wiersinga WJ, Wieland CW, Tjia IC, Day NP, Peacock SJ et al. Osteopontin impairs host defense during established gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis). PLoS Negl Trop Dis 2010;4.
20. van der Windt GJ, Hoogerwerf JJ, de Vos AF, Florquin S, van der Poll T. Osteopontin promotes host defense during Klebsiella pneumoniae-induced pneumonia. Eur Respir J 2010;36:1337-45.
21. van der Windt GJ, Hoogendijk AJ, Schouten M, Hommes TJ, de Vos AF, Florquin S et al. Osteopontin impairs host defense during pneumococcal pneumonia. J Infect Dis 2011;203:1850-8.
22. Vaschetto R, Nicola S, Olivieri C, Boggio E, Piccolella F, Mesturini R et al. Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med 2008;34:2176-84.
23. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999;18:4237-46.
24. Tuck AB, Hota C, Chambers AF. Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001;70:197-204.
25. Chiocchetti A, Comi C, Indelicato M, Castelli L, Mesturini R, Bensi T et al. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol 2005;163:172-8.
26. Inomata S, Shijubo N, Kon S, Maeda M, Yamada G, Sato N et al. Circulating interleukin-18 and osteopontin are useful to evaluate disease activity in patients with tuberculosis. Cytokine 2005;30:203-11.
27. Mishima R, Takeshima F, Sawai T, Ohba K, Ohnita K, Isomoto H et al. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol 2007;41:167-72.
28. Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:602-6.
29. Diao H, Liu X, Wu Z, Kang L, Cui G, Morimoto J et al. Osteopontin regulates interleukin-17 production in hepatitis. Cytokine 2012;60:129-37.
30. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000;12:613-20.
31. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000;165:1513-9.
32. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der PT. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002;168:3507-11.
33. Wiersinga WJ, Kager LM, Hovius JW, van der Windt GJ, de Vos AF, Meijers JC et al. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol 2010;184:3079-86.
34. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011;270:32-40.
35. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:23-31.
36. Savva A, Raftogiannis M, Baziaka F, Routsi C, Antonopoulou A, Koutoukas P et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect 2011;63:344-50.
37. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002;8:1132-41.
38. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-11.
39. Castelli GP, Pognani C, Cita M, Paladini R. Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med 2009;37:1845-9.
40. Mimoz O, Benoist JF, Edouard AR, Assicot M, Bohuon C, Samii K. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1998;24:185-8.